Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for pa...

Full description

Bibliographic Details
Main Authors:	Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Format:	Online
Language:	English
Published:	Springer Berlin Heidelberg 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099373/

id	pubmed-5099373
recordtype	oai_dc
spelling	pubmed-50993732016-11-21 Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma Alva, Ajjai Daniels, Gregory A. Wong, Michael K. K. Kaufman, Howard L. Morse, Michael A. McDermott, David F. Clark, Joseph I. Agarwala, Sanjiv S. Miletello, Gerald Logan, Theodore F. Hauke, Ralph J. Curti, Brendan Kirkwood, John M. Gonzalez, Rene Amin, Asim Fishman, Mayer Agarwal, Neeraj Lowder, James N. Hua, Hong Aung, Sandra Dutcher, Janice P. Original Article High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 %, partial response (PR) in 10 %, stable disease (SD) in 22 %, and 63 % had progressive disease (PD). The median overall survival (mOS) for these patients was 19.6 months, with a median follow-up of 43.1 months. The mOS was not reached for patients achieving CR or PR, and was 33.4 months for patients with SD. For patients with mRCC, 6 % achieved CR, 9 % had PR, 22 % had SD, and 62 % had PD. The mOS was 41 months, with a median follow-up of 46.6 months. The mOS for patients who had CR and PR was not reached and was 49.6 months for patients with SD. There were no treatment-related deaths among 362 patients. The duration of mOS for patients with mM and mRCC is longer than historically reported. These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents. Springer Berlin Heidelberg 2016-10-06 2016 /pmc/articles/PMC5099373/ /pubmed/27714434 http://dx.doi.org/10.1007/s00262-016-1910-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Alva, Ajjai Daniels, Gregory A. Wong, Michael K. K. Kaufman, Howard L. Morse, Michael A. McDermott, David F. Clark, Joseph I. Agarwala, Sanjiv S. Miletello, Gerald Logan, Theodore F. Hauke, Ralph J. Curti, Brendan Kirkwood, John M. Gonzalez, Rene Amin, Asim Fishman, Mayer Agarwal, Neeraj Lowder, James N. Hua, Hong Aung, Sandra Dutcher, Janice P.
spellingShingle	Alva, Ajjai Daniels, Gregory A. Wong, Michael K. K. Kaufman, Howard L. Morse, Michael A. McDermott, David F. Clark, Joseph I. Agarwala, Sanjiv S. Miletello, Gerald Logan, Theodore F. Hauke, Ralph J. Curti, Brendan Kirkwood, John M. Gonzalez, Rene Amin, Asim Fishman, Mayer Agarwal, Neeraj Lowder, James N. Hua, Hong Aung, Sandra Dutcher, Janice P. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
author_facet	Alva, Ajjai Daniels, Gregory A. Wong, Michael K. K. Kaufman, Howard L. Morse, Michael A. McDermott, David F. Clark, Joseph I. Agarwala, Sanjiv S. Miletello, Gerald Logan, Theodore F. Hauke, Ralph J. Curti, Brendan Kirkwood, John M. Gonzalez, Rene Amin, Asim Fishman, Mayer Agarwal, Neeraj Lowder, James N. Hua, Hong Aung, Sandra Dutcher, Janice P.
author_sort	Alva, Ajjai
title	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
title_short	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
title_full	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
title_fullStr	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
title_full_unstemmed	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
title_sort	contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
description	High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 %, partial response (PR) in 10 %, stable disease (SD) in 22 %, and 63 % had progressive disease (PD). The median overall survival (mOS) for these patients was 19.6 months, with a median follow-up of 43.1 months. The mOS was not reached for patients achieving CR or PR, and was 33.4 months for patients with SD. For patients with mRCC, 6 % achieved CR, 9 % had PR, 22 % had SD, and 62 % had PD. The mOS was 41 months, with a median follow-up of 46.6 months. The mOS for patients who had CR and PR was not reached and was 49.6 months for patients with SD. There were no treatment-related deaths among 362 patients. The duration of mOS for patients with mM and mRCC is longer than historically reported. These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents.
publisher	Springer Berlin Heidelberg
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099373/
_version_	1613716990889820160

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Similar Items